<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00096057</url>
  </required_header>
  <id_info>
    <org_study_id>ROCHE-NP17787</org_study_id>
    <secondary_id>UCLA-0402065-01</secondary_id>
    <secondary_id>CDR0000391212</secondary_id>
    <nct_id>NCT00096057</nct_id>
  </id_info>
  <brief_title>Monoclonal Antibody HuHMFG1 in Treating Women With Locally Advanced or Metastatic Breast Cancer</brief_title>
  <official_title>An Open Label Phase I Study of Humanized Human Milk Fat Globule-1 (huHMFG1) Antibody in Patients With Locally Advanced or Metastatic Breast Cancer (TOPCAT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies such as HuHMFG1 can locate tumor cells and either kill them&#xD;
      or deliver tumor-killing substances to them without harming normal cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of monoclonal antibody&#xD;
      HuHMFG1 in treating women with locally advanced or metastatic breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the safety and tolerability of monoclonal antibody HuHMFG1 in women with&#xD;
           locally advanced or metastatic breast cancer.&#xD;
&#xD;
        -  Determine a safe recommended dose and schedule of this drug in these patients.&#xD;
&#xD;
        -  Determine the pharmacokinetic profile, in the absence of any other chemotherapy or&#xD;
           endocrine agent, of this drug in these patients.&#xD;
&#xD;
        -  Determine the antitumor activity of this drug in these patients.&#xD;
&#xD;
        -  Determine time to progression in patients treated with this drug.&#xD;
&#xD;
        -  Assess immunological markers (e.g., granzyme B, gamma interferon, and C1Q) for&#xD;
           determining response to this drug in these patients.&#xD;
&#xD;
        -  Assess markers of immunogenicity (e.g., human anti-human antibody) of this drug in these&#xD;
           patients.&#xD;
&#xD;
        -  Assess tumor markers (e.g., CA15.3 and CEA) in patients treated with this drug.&#xD;
&#xD;
        -  Correlate, preliminarily, soluble HMFG1 antigen levels with pharmacokinetic data for&#xD;
           this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label, non-randomized, dose-escalation study.&#xD;
&#xD;
      Patients in cohorts 1 and 2 receive monoclonal antibody HuHMFG1 IV over 1-3 hours once every&#xD;
      21 days for doses 1 and 2. All subsequent dose intervals are based on individual half-life&#xD;
      value of the drug, to be within 3 days of the estimated half-life in multiples of 7 days.&#xD;
      Patients in cohorts 3 and 4 receive monoclonal antibody HuHMFG1 at the dosing interval&#xD;
      determined in the first 2 cohorts. Treatment continues in the absence of disease progression&#xD;
      or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 6 patients receive escalating doses of monoclonal antibody HuHMFG1 until the&#xD;
      maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at&#xD;
      which at least 2 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      All patients are followed at 4 weeks and then every 6 weeks for 6 months. Patients with an&#xD;
      antitumor response or stable disease are followed every 12 weeks until disease progression or&#xD;
      initiation of another antitumor treatment.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 6-24 patients will be accrued for this study within 18 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>monoclonal antibody HuHMFG1</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed breast cancer&#xD;
&#xD;
               -  Locally advanced or metastatic disease&#xD;
&#xD;
               -  No inflammatory breast cancer&#xD;
&#xD;
          -  Measurable (RECIST) or evaluable disease (e.g., cytologically or radiologically&#xD;
             detectable disease that does not fulfill RECIST criteria)&#xD;
&#xD;
          -  Failed prior OR not a candidate for OR refused anthracycline- and taxane-containing&#xD;
             chemotherapy&#xD;
&#xD;
          -  Patients whose tumor overexpresses HER-2 must have failed prior trastuzumab&#xD;
             (Herceptin®)&#xD;
&#xD;
          -  No known CNS metastases&#xD;
&#xD;
          -  No metastases accessible to complete surgical resection&#xD;
&#xD;
          -  Unstained slides cut from formalin-fixed and paraffin-embedded tumor blocks available&#xD;
&#xD;
               -  Appropriate tumor block also acceptable&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Sex&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  WHO 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 4 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Hemoglobin ≥ 10 g/dL&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  WBC ≥ 1,000/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 mg/dL&#xD;
&#xD;
          -  ALT or AST ≤ 2.5 times upper limit of normal (ULN) (&lt; 5 times ULN in patients with&#xD;
             liver metastases) OR&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2.5 times ULN (&lt; 5 times ULN in patients with liver metastases)&#xD;
&#xD;
               -  Any degree of elevated alkaline phosphatase allowed provided it is due to bone&#xD;
                  metastases&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN OR&#xD;
&#xD;
          -  Creatinine clearance &gt; 60 mL/min&#xD;
&#xD;
          -  Uric acid &lt; 1.25 times ULN (for patients with hyperuricemia only)&#xD;
&#xD;
          -  Calcium (corrected for serum albumin) &lt; 11.5 mg/dL (for patients with hypercalcemia&#xD;
             only)&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  LVEF ≥ 45% by MUGA or echocardiogram within the past 4 weeks&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective barrier contraception&#xD;
&#xD;
          -  No other malignancy within the past 5 years except adequately treated nonmelanoma skin&#xD;
             cancer or cervical intra-epithelial neoplasia&#xD;
&#xD;
          -  No other uncontrolled illness that would preclude study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Prior biological therapy allowed&#xD;
&#xD;
          -  More than 2 weeks since prior blood transfusions or growth factors to aid&#xD;
             hematological recovery&#xD;
&#xD;
          -  No other concurrent antitumor immunotherapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 4 weeks since prior cytotoxic chemotherapy&#xD;
&#xD;
          -  No more than 3 prior chemotherapy regimens, including adjuvant/neoadjuvant therapy&#xD;
&#xD;
          -  No concurrent antitumor chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Prior hormonal therapy allowed&#xD;
&#xD;
          -  No concurrent corticosteroids except as physiologic replacement and/or for acute&#xD;
             short-term treatment of, or prophylaxis against, infusion reactions&#xD;
&#xD;
          -  No concurrent antitumor hormonal therapy&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy (except for palliative radiotherapy)&#xD;
&#xD;
          -  No concurrent antitumor radiotherapy, except for palliation to non-study lesions&#xD;
&#xD;
               -  Irradiated area should be as small as possible and involve ≤ 10% of the bone&#xD;
                  marrow in any given 4-week period&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  More than 4 weeks since prior major surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 30 days since prior investigational agents&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark D. Pegram, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center at UC Health Sciences Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M.D. Anderson Cancer Center at University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2007</verification_date>
  <study_first_submitted>November 9, 2004</study_first_submitted>
  <study_first_submitted_qc>November 8, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2004</study_first_posted>
  <last_update_submitted>June 25, 2013</last_update_submitted>
  <last_update_submitted_qc>June 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2013</last_update_posted>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

